FDA – Page 76 – Pharma.Tips

Container closure integrity risk during development – regulatory risk analysis and mitigation

Mitigating Container Closure Integrity Risks During Development: An Investigation Approach Container closure integrity (CCI) is a pivotal aspect in the pharmaceutical sector, particularly during the packaging development phase. A compromise…

Literature surveillance failure during inspection – CAPA for PV system weaknesses

Addressing Failures in Literature Surveillance During Inspection: A CAPA Approach In the pharmaceutical sector, effective pharmacovigilance (PV) is crucial, with literature surveillance serving as a significant component in monitoring drug…

Artwork change error during market launch – how to prevent recall triggers

Addressing Artwork Change Errors During Market Launch to Mitigate Recall Triggers Artwork change errors can have significant implications for pharmaceutical companies, especially during critical phases such as market launches. Such…

Periodic report inconsistencies during signal review – preventing repeat PV findings

Addressing Inconsistencies in Periodic Reports During Signal Review to Prevent Future PV Findings Periodic reports are integral to pharmacovigilance, and inconsistencies within these documents can lead to regulatory scrutiny and…

Artwork change error during inspection readiness – regulatory risk analysis and mitigation

Analyzing Artwork Change Errors During Inspection Readiness: A Practical Approach to Regulatory Risk Management In the pharmaceutical industry, the integrity of product labeling and artwork is critical to compliance, patient…

AE reporting non-compliance during post-marketing surveillance – how to strengthen benefit–risk documentation

Addressing Non-Compliance in AE Reporting During Post-Marketing Surveillance: An Investigative Approach The pharmaceutical industry faces stringent requirements around adverse event (AE) reporting during post-marketing surveillance, a critical component in evaluating…

Extractables and leachables concern during market launch – how to prevent recall triggers

Managing Extractables and Leachables Issues before Market Launch In pharmaceutical manufacturing, the presence of extractables and leachables (E&L) from packaging can lead to significant regulatory concerns, particularly during a product’s…

PV system audit finding during inspection – CAPA for PV system weaknesses

“`html Conducting a Thorough Investigation of PV System Audit Findings During Regulatory Inspections During regulatory inspections, findings related to Pharmacovigilance (PV) systems can reveal critical weaknesses that may jeopardize compliance…

PV system audit finding during inspection – CAPA for PV system weaknesses

Addressing Gaps Identified in PV System Audits: An Investigative Approach Pharmaceutical professionals are often faced with the challenge of ensuring compliance within Pharmacovigilance (PV) systems, especially during regulatory inspections. When…

Stability impact underestimated during market launch – inspection evidence expectations

Understanding Underestimated Stability Impacts During Market Launch and Inspection Evidence Expectations In the highly regulated pharmaceutical industry, the launch of a new product must be treated with utmost scrutiny to…

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Strengthening Documentation Following a PV System Audit Finding in Benefit-Risk Assessment Pharmaceutical companies face significant pressure to maintain compliance and robustness in their pharmacovigilance (PV) systems, particularly during benefit-risk assessments.…

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Investigating Audit Findings in Pharmacovigilance Systems: Enhancing Benefit-Risk Documentation Pharmaceutical companies often face a multitude of challenges arising from internal audits, particularly regarding the documentation of benefit-risk assessments in Pharmacovigilance…